Galmed Pharmaceuticals Ltd. announced the grant of a European patent related to the use of a combination of Aramchol and Resmetirom (MGL-3196, REZDIFFRA) for the treatment of NASH/MASH and liver fibrosis. The patent was granted in France, Germany, Italy, the Netherlands and the United Kingdom and the approval of the patent in the United States and other countries is pending. With this latest patent, Galmed is strengthening and extending the patent protection of its lead compound, Aramchol, until September 2039.

Previously, Galmed reported results from the Open-Label part of its Phase 3 NASH study, which demonstrated that treatment with Aramchol 300mg BID resulted in a high rate of subjects with fibrosis improvement. Galmed has long believed that the optimum treatment for NASH/MASH will be combination therapy. Aramchol has been shown to down-regulate the expression and activity of stearoyl-CoA desaturase-1 (SCD1) in hepatic stellate cells, resulting in a direct effect on fibrogenesis.

Aramchol?s unique mechanism of action differs from others in its competitive landscape, positioning it to work as a potent anti-fibrotic compound alongside effective treatments in both approved and pre-approval stages.